Press releases
GeNeuro SA Announces an Extraordinary Shareholders’ Meeting on June 30, 2025
Geneva, Switzerland, 10 June 2025 – 6:00 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that it will hold an extraordinary shareholders’ meeting on June 30, 2025.
As previously disclosed, GeNeuro is subject to a definitive debt-restructuring moratorium granted by the Geneva Tribunal of First Instance on 26 May 2025. In this context, the Company is not in a position to finalize and present its audited annual accounts for the financial year ending 31 December 2024. Consequently, it cannot hold its Ordinary Annual General Meeting within six months of year-end, as required under Swiss corporate law.
Pursuant to the Company’s Articles of Association and applicable Swiss legal provisions, the mandates of the current members of the Board of Directors will expire on 30 June 2025. To ensure continuity of governance, the Extraordinary General Meeting has been convened to vote on the re-election of the Board members, of the Chairman, of the Remuneration Committee, and of the Independent Proxy until the next Annual General Meeting can be held.
The notice to the meeting is published today in the Swiss Official Gazette of Commerce.
Contacts GeNeuro
| Jesús Martin-Garcia |
| Chairman and CEO |
| investors@geneuro.com |
GeNeuro SA Announces Definitive Debt-Restructuring Moratorium
Geneva, Switzerland, 27 May 2025 – 6:00 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court of First Instance has, in a May 26, 2025, judgment, granted GeNeuro SA a four-month definitive debt-restructuring moratorium, under the continued supervision of the court-appointed commissary.
French Press release
GeNeuro SA announces the postponement of the publication of the Company’s 2024 annual results
Geneva, Switzerland, 12 May 2025 – 6:00 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces the postponement of the publication of its December 31, 2024 annual results and annual financial report in order to be able to take into account the financial impacts of the restructuring targeted by the Company as part of the granted debt-restructuring moratorium procedure. The Company will announce by press release the new date of their approval and publication.
Français:
GeNeuro SA Announces Renewal of Provisional Debt-Restructuring Moratorium
Geneva, Switzerland, 28 January 2025 – 6:00 pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court of First Instance has renewed the provisional debt-restructuring moratorium granted to the Company in September 2024. The moratorium has been extended for an additional four months, until May 27, 2025, under the continued supervision of a court-appointed commissary.
New data supporting a new precision medicine approach for ALS patients with GeNeuro’s GNK-301 presented at the 35th International Symposium on ALS/MND
Geneva, Switzerland, December 6, 2024 – 6:30 pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on addressing the factors driving the progression of neurodegenerative and autoimmune diseases, such as amyotrophic lateral sclerosis (ALS), today announced that groundbreaking findings on a potential precision medicine strategy for ALS with GeNeuro’s GNK-301 were presented at the 35th International Symposium on ALS/MND, taking place in Montreal, Canada, from December 6-8, 2024. The presentation was delivered by Dr. Darshan Pandya, from National Institute of Neurological Disorders and Stroke (NINDS)/National Institutes of Health (NIH).
GeNeuro SA obtains the opening of debt-restructuring proceedings
Geneva, Switzerland, 30 September 2024 – 7:00 am CEST – GeNeuro (Euronext Paris: CH0308403085 – G NRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court of First Instance has approved its application for a debt-restructuring moratorium dated July 15, 2024, aimed at restructuring its debts and finding solutions for the continuity of its activities in the interests of all stakeholders.